US20060280774A1
(en)
*
|
1995-06-02 |
2006-12-14 |
Allergan, Inc. |
Compositions and methods for treating glaucoma
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
EP1003569B1
(de)
*
|
1997-08-11 |
2004-10-20 |
Allergan, Inc. |
Steriles retinoid enthaltendes biodegradierbares implantat mit verbesserter biocompatibilität und verfahren zu dessen herstellung
|
US6306426B1
(en)
*
|
1997-08-11 |
2001-10-23 |
Allergan Sales, Inc. |
Implant device with a retinoid for improved biocompatibility
|
EP1154691A4
(de)
*
|
1999-01-05 |
2004-07-07 |
Massachusetts Eye & Ear Infirm |
Gezielte transsklerale gesteuerte wirkstoffabgabe an die retina und choroidae
|
US6416777B1
(en)
|
1999-10-21 |
2002-07-09 |
Alcon Universal Ltd. |
Ophthalmic drug delivery device
|
PT1221918E
(pt)
|
1999-10-21 |
2005-06-30 |
Alcon Inc |
Administracao de drogas sub-tenon
|
US7943162B2
(en)
|
1999-10-21 |
2011-05-17 |
Alcon, Inc. |
Drug delivery device
|
CN1292721C
(zh)
*
|
1999-10-21 |
2007-01-03 |
爱尔康公司 |
药物释放装置
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
ES2312456T3
(es)
*
|
2000-08-30 |
2009-03-01 |
Johns Hopkins University |
Dispositivos para suministro intraocular de farmacos.
|
DE60114229T2
(de)
*
|
2000-11-29 |
2006-07-06 |
Allergan, Inc., Irvine |
Verhinderung von transplantatabstossung im auge
|
CN1203814C
(zh)
|
2001-07-23 |
2005-06-01 |
爱尔康公司 |
眼部药物输送装置
|
WO2003009784A1
(en)
|
2001-07-23 |
2003-02-06 |
Alcon, Inc. |
Ophthalmic drug delivery device
|
FI118172B
(fi)
|
2002-04-22 |
2007-08-15 |
Inion Ltd |
Kirurginen implantti
|
WO2003092665A2
(en)
*
|
2002-05-02 |
2003-11-13 |
Massachusetts Eye And Ear Infirmary |
Ocular drug delivery systems and use thereof
|
US7678827B2
(en)
|
2002-07-15 |
2010-03-16 |
Alcon, Inc. |
Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use
|
US20070184089A1
(en)
*
|
2002-07-15 |
2007-08-09 |
Alcon, Inc. |
Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
WO2004073551A2
(en)
*
|
2003-02-18 |
2004-09-02 |
Massachusetts Eye And Ear Infirmary |
Transscleral drug delivery device and related methods
|
US8404269B2
(en)
*
|
2003-04-11 |
2013-03-26 |
Michael Snyder |
Sustained release implantable eye device
|
DE602004028638D1
(de)
*
|
2003-05-02 |
2010-09-23 |
Surmodics Inc |
System zur kontrollierten Freisetzung eines bioaktiven Wirkstoffs im hinteren Bereich des Auges
|
US8246974B2
(en)
|
2003-05-02 |
2012-08-21 |
Surmodics, Inc. |
Medical devices and methods for producing the same
|
US20040253293A1
(en)
*
|
2003-06-16 |
2004-12-16 |
Afshin Shafiee |
Rate controlled release of a pharmaceutical agent in a biodegradable device
|
CA2522592A1
(en)
*
|
2003-07-10 |
2005-02-03 |
Alcon, Inc. |
Ophthalmic drug delivery device
|
US7585517B2
(en)
*
|
2003-09-18 |
2009-09-08 |
Macusight, Inc. |
Transscleral delivery
|
US20050250737A1
(en)
*
|
2003-11-12 |
2005-11-10 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
US20070224278A1
(en)
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20050101582A1
(en)
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
KR20070051768A
(ko)
*
|
2003-12-02 |
2007-05-18 |
알러간, 인코포레이티드 |
레티노이드를 사용한 광수용체 변성의 방지 및/또는 감소
|
ES2318453T3
(es)
|
2004-01-20 |
2009-05-01 |
Allergan, Inc. |
Composiciones para terapia localizada del ojo, que comprenden, de preferencia,triamcinolona acetonida y acido hialuronico.
|
US20050244472A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
US20060182781A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Methods for treating ocular conditions with cyclic lipid contraining microparticles
|
US8425929B2
(en)
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
US20050244463A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US8673341B2
(en)
*
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US8591885B2
(en)
*
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
US20060182783A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US20070212395A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Allergan, Inc. |
Ocular therapy using sirtuin-activating agents
|
AU2005240078A1
(en)
*
|
2004-04-30 |
2005-11-17 |
Allergan, Inc. |
Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
US8529927B2
(en)
*
|
2004-04-30 |
2013-09-10 |
Allergan, Inc. |
Alpha-2 agonist polymeric drug delivery systems
|
BRPI0510485A
(pt)
|
2004-04-30 |
2007-11-13 |
Allergan Inc |
implantes inibidores de tirosina cinase intravìtreos biodegradáveis
|
US8722097B2
(en)
*
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US20050244500A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
US7589057B2
(en)
|
2004-04-30 |
2009-09-15 |
Allergan, Inc. |
Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US20070059336A1
(en)
*
|
2004-04-30 |
2007-03-15 |
Allergan, Inc. |
Anti-angiogenic sustained release intraocular implants and related methods
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20060024350A1
(en)
*
|
2004-06-24 |
2006-02-02 |
Varner Signe E |
Biodegradable ocular devices, methods and systems
|
BRPI0513243B8
(pt)
*
|
2004-07-12 |
2021-05-25 |
Allergan Inc |
composições oftálmicas e respectivos usos
|
WO2006023130A2
(en)
*
|
2004-08-12 |
2006-03-02 |
Surmodics, Inc. |
Biodegradable controlled release bioactive agent delivery device
|
US8663639B2
(en)
*
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
DK1848431T3
(en)
*
|
2005-02-09 |
2016-04-18 |
Santen Pharmaceutical Co Ltd |
LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
|
US20060233858A1
(en)
*
|
2005-03-08 |
2006-10-19 |
Allergan, Inc. |
Systems and methods providing targeted intraocular drug delivery
|
JP2008535847A
(ja)
*
|
2005-04-08 |
2008-09-04 |
サーモディクス,インコーポレイティド |
網膜下に送達するための持続放出インプラント
|
US7931909B2
(en)
*
|
2005-05-10 |
2011-04-26 |
Allergan, Inc. |
Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
|
JP5222134B2
(ja)
|
2005-06-15 |
2013-06-26 |
ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション |
Her−2ペプチド
|
BRPI0615962A2
(pt)
|
2005-07-27 |
2011-05-31 |
Univ Florida |
uso de um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lisossomal, um inibidor do trasporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador da resposta a choque térmico, um inibidor de glicosidade, e um inibidor de histona deacetilase, uso de 11-cis-retinal ou 9-cis-retinal e um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lissosomal, um inibidor do transporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador de resposta a choque térmico, um inibidor de glicosidase, e um inibidor de histona deacetilase, método para aumentar a quantidade de um conformação bioquimicamente funcional de uma proteìna em uma célula, composição farmacêutica para o tratamento de um pcd ocular, composição farmacêutica para o tratamento de retinite pigmentosa, kit para o tratamento de um pcd ocular, kit para o tratamento de retinite pigmentosa, método para a identificação de um composto útil para o tratamento de um indivìduo que tem um pcd ocular, método para a identificação de um composto útil para o tratamento de um indivìduo que tem retinite pigmentosa, uso de um inibidor proteassomal ou um inibidor de autofagia e método para a produção de uma proteìna recombinante em uma conformação bioquimicamente funcional
|
CA2621597C
(en)
*
|
2005-09-21 |
2014-06-10 |
Surmodics, Inc. |
In vivo formed matrices including natural biodegradable polysaccharides and ophthalmic uses thereof
|
EP1937210B1
(de)
*
|
2005-10-18 |
2017-05-31 |
Allergan, Inc. |
Augentherapie mittels selektiver penetration posteriorer segmentgewebe mit glucocorticoid-derivaten
|
EA016227B1
(ru)
|
2005-11-29 |
2012-03-30 |
Смитклайн Бичем Корпорейшн |
Способ лечения офтальмологических неоваскулярных расстройств
|
US20070178138A1
(en)
*
|
2006-02-01 |
2007-08-02 |
Allergan, Inc. |
Biodegradable non-opthalmic implants and related methods
|
WO2008029276A2
(en)
|
2006-02-02 |
2008-03-13 |
Allergan, Inc. |
Compositions and methods for the treatment of ophthalmic disease
|
JP5528708B2
(ja)
|
2006-02-09 |
2014-06-25 |
参天製薬株式会社 |
安定な製剤ならびにそれらを調製および使用する方法
|
CN101443004B
(zh)
|
2006-03-23 |
2013-03-06 |
参天制药株式会社 |
用于与血管通透性有关的疾病或病症的制剂
|
US20070260203A1
(en)
*
|
2006-05-04 |
2007-11-08 |
Allergan, Inc. |
Vasoactive agent intraocular implant
|
US7946296B2
(en)
*
|
2006-05-26 |
2011-05-24 |
Philip Morris Usa Inc. |
Dissolvable tobacco film strips and method of making the same
|
US8668676B2
(en)
*
|
2006-06-19 |
2014-03-11 |
Allergan, Inc. |
Apparatus and methods for implanting particulate ocular implants
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20070298073A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20080020014A1
(en)
*
|
2006-07-19 |
2008-01-24 |
Paul Consigny |
Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
|
US20080097335A1
(en)
*
|
2006-08-04 |
2008-04-24 |
Allergan, Inc. |
Ocular implant delivery assemblies
|
CL2007002958A1
(es)
*
|
2006-10-12 |
2008-05-09 |
Epix Delaware Inc |
Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
US8586556B2
(en)
*
|
2006-11-03 |
2013-11-19 |
Allergan, Inc. |
Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
|
CA2670990A1
(en)
|
2006-12-01 |
2008-06-12 |
Allergan, Inc. |
Method for determining optimum intraocular locations for drug delivery systems
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
US20080147021A1
(en)
*
|
2006-12-15 |
2008-06-19 |
Jani Dharmendra M |
Drug delivery devices
|
US8846073B2
(en)
|
2006-12-19 |
2014-09-30 |
Allergan, Inc. |
Low temperature processes for making cyclic lipid implants for intraocular use
|
US20080265343A1
(en)
*
|
2007-04-26 |
2008-10-30 |
International Business Machines Corporation |
Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
|
US8231892B2
(en)
*
|
2007-05-24 |
2012-07-31 |
Allergan, Inc. |
Biodegradable drug delivery system
|
JP2010539245A
(ja)
|
2007-09-14 |
2010-12-16 |
日東電工株式会社 |
薬物担体
|
EP2280766A1
(de)
|
2007-12-11 |
2011-02-09 |
CytoPathfinder, Inc. |
Carboxamid-verbindungen und ihre verwendung als chemokin-rezeptor-agonisten
|
US10588855B2
(en)
|
2008-05-12 |
2020-03-17 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US9877973B2
(en)
|
2008-05-12 |
2018-01-30 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US8202531B2
(en)
*
|
2008-07-23 |
2012-06-19 |
Warsaw Orthopedic, Inc. |
Drug depots having one or more anchoring members
|
CN101386203B
(zh)
*
|
2008-10-15 |
2011-09-14 |
广州卫视博生物科技有限公司 |
折叠式人工玻璃体制造方法及其模具
|
US9095506B2
(en)
|
2008-11-17 |
2015-08-04 |
Allergan, Inc. |
Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
|
US8034813B2
(en)
|
2008-11-18 |
2011-10-11 |
Bausch & Lomb Incorporated |
Polymorphs of brimonidine pamoate
|
US8545554B2
(en)
*
|
2009-01-16 |
2013-10-01 |
Allergan, Inc. |
Intraocular injector
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
US8632511B2
(en)
|
2009-05-06 |
2014-01-21 |
Alcon Research, Ltd. |
Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
|
IN2012DN00352A
(de)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
WO2011039648A1
(en)
|
2009-09-30 |
2011-04-07 |
Glaxo Wellcome Manufacturing Pte Ltd. |
Methods of administration and treatment
|
CN102724951A
(zh)
|
2009-11-09 |
2012-10-10 |
阿勒根公司 |
用于刺激毛发生长的组合物和方法
|
US8177747B2
(en)
|
2009-12-22 |
2012-05-15 |
Alcon Research, Ltd. |
Method and apparatus for drug delivery
|
US9133082B2
(en)
|
2011-06-14 |
2015-09-15 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US8772273B2
(en)
|
2011-10-04 |
2014-07-08 |
Quretino Therapeutics, Inc. |
Formulations and uses of retinoic acid receptor selective agonists
|
US9499464B2
(en)
|
2011-10-19 |
2016-11-22 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2785346A4
(de)
|
2011-11-30 |
2015-04-29 |
Bikam Pharmaceuticals Inc |
Opsinbindende liganden, zusammensetzungen damit und anwendungsverfahren dafür
|
AU2012346537A1
(en)
|
2011-12-01 |
2014-07-17 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US9308355B2
(en)
|
2012-06-01 |
2016-04-12 |
Surmodies, Inc. |
Apparatus and methods for coating medical devices
|
US9827401B2
(en)
|
2012-06-01 |
2017-11-28 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
US11090468B2
(en)
|
2012-10-25 |
2021-08-17 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
CA2901280A1
(en)
|
2013-02-15 |
2014-08-21 |
Allergan, Inc. |
Sustained drug delivery implant
|
US10883108B2
(en)
|
2016-03-31 |
2021-01-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
US11229662B2
(en)
|
2016-11-15 |
2022-01-25 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
|
CA3082643A1
(en)
|
2017-11-14 |
2019-05-23 |
The Schepens Eye Research Institute, Inc. |
Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
WO2020112816A1
(en)
|
2018-11-29 |
2020-06-04 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
US11819590B2
(en)
|
2019-05-13 |
2023-11-21 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
CN111861124B
(zh)
*
|
2020-06-18 |
2023-07-25 |
汕头大学 |
适用于注塑机的可识别性能评估方法、系统及存储介质
|
WO2023105417A1
(en)
|
2021-12-06 |
2023-06-15 |
Breye Therapeutics Aps |
Danegaptide formulation for applicatoin in the eye
|